RX-2 is a human-derived mixed cytokine product containing more than 29 cytokines that promote or enhance a complex immune response. Scientists are developing IRX-2 as a cancer immunotherapy. IRX-2 is administered as a subcutaneous injection around lymph node beds near the tumor target.

IRX-2 is produced under cGMP (current good manufacturing process) conditions following stimulation of a particular set of human peripheral blood mononuclear cells (PBMCs) by phytohaemagglutinin (PHA). Cytokine production induced by PHA mimics that seen after brisk stimulation of human immune cells by an immunogenic pathogen or an infection. We obtain source material PBMCs from FDA-licensed blood banks. Preclinical data from animal and in vitro studies, as well as biologic data from patients in clinical trials, demonstrate that IRX-2 acts in multiple ways to augment the immune response and influence the target tumor microevironment.

Data collected to date suggest that IRX-2 reduces the immune suppression often seen in cancer tumors. This immunomodulatory activity appears to occur by restoring immune function and activating a coordinated immune response against the tumor.